Predict your next investment

CDx Diagnostics company logo
HEALTHCARE | Disease Diagnosis

See what CB Insights has to offer

Founded Year



Unattributed - II | Alive

Total Raised


Last Raised

$5M | 2 yrs ago

About CDx Diagnostics

CDx Diagnostics specializes in the detection and prevention of cancers of the esophagus, oral cavity, pharynx, and larynx. CDx Diagnostics provides clinicians with tools to enhance their detection of precancerous change through more complete epithelial sampling combined with computer-assisted morphological and molecular laboratory analysis.

CDx Diagnostics Headquarter Location

Two Executive Boulevard Suite 102

Suffern, New York, 10901,

United States


Latest CDx Diagnostics News

CDx Diagnostics’ ​​WATS3D Receives “Medically Necessary” Designation From Highmark Health Plans

Nov 17, 2021

Highmark Blue Cross Blue Shield, Highmark BCBS Delaware, and Highmark BCBS West Virginia join numerous payors in creating positive medical policy for WATS3D November 17, 2021 09:00 AM Eastern Standard Time SUFFERN, N.Y.--( BUSINESS WIRE )--WATS3D, a diagnostic platform developed by CDx Diagnostics to empower physicians to detect Barrett’s esophagus (BE) and esophageal dysplasia, has been designated as medically necessary by Highmark Blue Cross Blue Shield plans in Delaware, Pennsylvania, and West Virginia. Clinically proven to significantly increase the detection rate of BE, pre-cancer, and cancerous cells in the esophagus compared to the traditional screening methods, WATS3D is now a covered benefit for more than 3.6 million Highmark members. WATS3D, which is intended as an adjunct to standard four-quadrant biopsies for screening, diagnosis, or surveillance of cancerous or precancerous esophageal lesions, may be considered medically necessary for the surveillance of both Barrett’s esophagus and chronic gastroesophageal reflux disease (GERD). “Highmark Blue Cross Blue Shield’s positive medical policy for WATS3D demonstrates the momentum CDx Diagnostics has built, bringing access to WATS3D to a total of 10 Million members.” said Bill Huffnagle, CEO of CDx Diagnostics. “By empowering healthcare professionals to stop cancer before it starts, CDx helps physicians and payors improve patient outcomes through our potentially life-saving technology.” WATS3D technology helps clinicians to overcome the limitations associated with traditional upper endoscopy screening and surveillance methods, by combining a specially designed brush, unique 3D imaging powered by artificial intelligence, and a team of trained GI pathologists. In large multicenter clinical studies, WATS3D has been found to significantly increase the detection rate of BE and esophageal dysplasia, both treatable precursors to esophageal cancer, one of the fastest growing and most fatal cancers in the United States. WATS3D testing meets the five pillars of evidence-based medicine typically required by insurance payors: analytic validity, clinical validity, clinical utility, cost-effectiveness, and recommendations by major medical societies. The American Society for Gastrointestinal Endoscopy (ASGE), the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES), and the American Foregut Society (AFS) each currently include WATS3D testing in their recommendations. Since 2019, the ASGE has included WATS3D in its Standards of Practice Committee’s guideline for the screening and surveillance of BE. In 2020, the technology was deemed a safe and effective adjunct to forceps biopsies in the evaluation of BE, low-grade dysplasia, and high-grade dysplasia by SAGES Technology and Value Assessment Committee (TAVAC). About CDx Diagnostics CDx Diagnostics’ mission of Empowering Physicians with Innovative Technology to Prevent Esophageal Cancer, One Patient at a Time is accomplished by a proprietary diagnostic platform that synthesizes computer imaging, artificial intelligence, molecular biology and three-dimensional cytopathology to detect precancerous change earlier and more reliably than prior methods. CDx tests require only a few minutes of practice time, are highly cost effective, widely reimbursed, and address a recognized critical gap in the current diagnostic standard of care that results in thousands of otherwise unnecessary cancer deaths each year. Routine clinical use of WATS3D testing has already detected thousands of cancers that would otherwise have been missed in time for effective endoscopic treatment and application of the CDx Diagnostics platform to prevent cancers of the bile duct, stomach, and IBD affected colon is currently in progress. CDx Diagnostics is a Galen Partners portfolio company. To learn more, visit . Contacts

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing CDx Diagnostics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

CDx Diagnostics is included in 5 Expert Collections, including Medical Devices.


Medical Devices

7,889 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.


Biopharma Tech

15,532 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.



3,605 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.


Health Monitoring & Diagnostics

2,707 items

Companies developing or offering products that aid in the assessment, screening, diagnosis, or monitoring of a person's state of health/wellness. Excludes companies focused solely on fitness/sports performance


Digital Health

12,248 items

Technologies, platforms, and systems that engage consumers for lifestyle, wellness, or health-related purposes; capture, store, or transmit health data; and/or support life science and clinical operations. (DiME, DTA, HealthXL, & NODE.Health)

CDx Diagnostics Patents

CDx Diagnostics has filed 1 patent.

patents chart

Application Date

Grant Date


Related Topics



Inflammations, Autoimmune diseases, Gastrointestinal tract disorders, Gastroenterology, Abdominal pain


Application Date


Grant Date


Related Topics

Inflammations, Autoimmune diseases, Gastrointestinal tract disorders, Gastroenterology, Abdominal pain



CDx Diagnostics Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

CDx Diagnostics Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.